Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 275-833-8 | CAS number: 71675-87-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 3 September 2014 - 23 September 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- 4-amino-5-(ethylsulphonyl)-o-anisic acid
- EC Number:
- 275-833-8
- EC Name:
- 4-amino-5-(ethylsulphonyl)-o-anisic acid
- Cas Number:
- 71675-87-1
- Molecular formula:
- C10H13NO5S
- IUPAC Name:
- 4-amino-5-(ethanesulfonyl)-2-methoxybenzoic acid
Constituent 1
- Specific details on test material used for the study:
- Details on test material
- Name of test material (as cited in study report): 4-amino-5-ethylsulfonyl-2-methoxybenzoic acid
- Physical state: Solid
- Analytical purity: 99.81%
- Lot/batch No.: MP1032.31
- Expiration date of the lot/batch: 16 June 2017
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA
- Remarks:
- CBA/J Rj mice
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: ELEVAGE JANVIER, Route des Chènes Secs B.P. 4105, 53940 LE GENEST-ST-ISLE, France
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 9 weeks old
- Weight at study initiation: 20.3-21.9 g (the weight variation in animals in the study did not exceed ± 20% of the mean weight)
- Housing: Group caging / mice were provided with glass tunnel-tubes. Cage Type II. polypropylene / polycarbonate.
- Diet (e.g. ad libitum): ad libitum, ssniff® SM Rat/Mouse – “Breeding & Maintenance, 15 mm, autoclavable Complete diet for rats/mice”
- Water (e.g. ad libitum): ad libitum, tap water.
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20.3-26.8 °C
- Humidity (%): 33-79 %
- Air changes (per hr): 15-20 air exchanges/hour
- Photoperiod (hrs dark / hrs light): 12 hours daily, from 6.00 a.m. to 6.00 p.m.
Study design: in vivo (LLNA)
- Vehicle:
- dimethylformamide
- Remarks:
- According to the recommendation of the relevant OECD guideline, DMF was selected for vehicle of the study.
- Concentration:
- 0 (control), 10, 25, 50 %
- No. of animals per dose:
- 4
- Details on study design:
- RANGE FINDING TESTS:
- Compatibility test: The following solvents were analysed: Acetone: Olive oil 4:1 (v/v) mixture (AOO), N,N-Dimethyl formamide (DMF), Methyl ethyl ketone (MEK), Propylene glycol (PG), Dimethyl sulfoxide (DMSO) and 1% aqueous Pluronic PE9200 (1% Pluronic) as vehicles.The maximum achievable concentration of test substance was 50 % (w/v) in DMF according the OECD guideline.
- Preliminary Irritation/Toxicity Test: Two animals(13 week of age and 24.1-24.5 grams) per dose were exposed to 50 and 25 % (w/v) test item in DMF. Animals were treated as in the main test but it was terminated on Day 6 with a body weight measurement. All mice were observed daily for clinical signs of systemic toxicity or local irritation at the application site. Both ears of each mouse were observed for erythema. Ear thickness was measured using a thickness gauge on Day 1 (pre-dose), Day 3 (48 hours after the first dose) and Day 6. Additional quantification of the ear thickness was performed by ear punch weight determination after the euthanasia. No mortality or signs of systemic toxicity were observed. No marked body weight loss was observed. Test item precipitate was observed in the 50% (w/v) dose group on Days 1-4 and in the 25% (w/v) dose group on Days 2-3. No significant increase was observed in the ear thickness. The draining auricular lymph nodes of the animals had a normal appearance. Based on these results, 50 and 25% (w/v) doses were considered to be acceptable for the main test.
MAIN STUDY
TREATMENT PREPARATION AND ADMINISTRATION:
- Criteria used to consider a positive response: The test item is regarded as a sensitizer if both of the following criteria are fulfilled:
*That exposure to at least one concentration of the test item resulted in an incorporation of 3HTdR at least 3-fold or greater than recorded in
control mice, as indicated by the stimulation index.
*The data are compatible with a conventional dose response, although allowance must be made for either local toxicity or immunological suppression.
TREATMENT PREPARATION AND ADMINISTRATION:
Animals were topically dosed with 25 μL on the dorsal surface of each ear once a day for three consecutive days (Days 1, 2 and 3). There was no treatment on
Days 4, 5 and 6. On day 6, each mouse received an injection of 250μl of sterile PBS (phosphate buffered saline) containing aprox. 20 μCi of 3HTdR. Five hours
later, the mice were euthanized and the auricular lymph nodes were extracted from the animals. A single cell suspension (SCS) of pooled lymph node cells
(LNCs) was prepared and the samples were prepared to be examined in a β-scintillation counter.
OBSERVATIONS:
During the study (Day 1 to Day 6) each animal was observed daily for clinical signs, local irritation and systemic toxicity. Clinical observations were performed
twice a day (before and after treatments) on Days 1, 2 and 3 and once daily on Days 4, 5 and 6. Individual body weights were recorded on Day 1 (beginning of
the test) and on Day 6 (prior to 3HTdR injection).
EVALUATION OF RESULTS:
Radioactive disintegrations per minute (DPM) was measured for each pooled group of nodes and corrected with the background DPM value. The results were
expressed as “DPN” (DPM divided by the number of lymph nodes). Stimulation index (SI = DPN value of a treated group divided by the DPN value of the
negative control group) for each treatment group was also calculated. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- - Criteria used to consider a positive response:
The test item is regarded as a sensitizer if both of the following criteria are fulfilled:
*That exposure to at least one concentration of the test item resulted in an incorporation of 3HTdR at least 3-fold or greater than recorded in control mice, as indicated by the stimulation index.
*The data are compatible with a conventional dose response, although allowance must be made for either local toxicity or immunological suppression.
Results and discussion
- Positive control results:
- The positive control substance was examined at a concentration of 25% (w/v) in the relevant vehicle (DMF) using CBA/J Rj mice. No mortality, cutaneous reactions or signs of toxicity were observed for the positive control substance in the study. A significant lymphoproliferative response (stimulation index value of 4.8) was noted for HCA in the main experiment. This value was considered to confirm the appropriate performance of the assay.
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- SI
- Value:
- ca. 0.7
- Test group / Remarks:
- Tets item (50% (w/v) in DMF)
- Remarks on result:
- other: No indication of skin sensitisation
- Key result
- Parameter:
- SI
- Value:
- ca. 0.6
- Test group / Remarks:
- Test item (25% (w/v) in DMF)
- Remarks on result:
- other: No indication of skin sensitisation
- Key result
- Parameter:
- SI
- Value:
- ca. 1
- Test group / Remarks:
- Test item (10% (w/v) in DMF)
- Remarks on result:
- other: No indication of skin sensitisation
- Parameter:
- other: EC 1.6
- Remarks on result:
- not determinable
- Cellular proliferation data / Observations:
- CELLULAR PROLIFERATION DATA: See : Any other information on results below.
DETAILS ON STIMULATION INDEX CALCULATION :SI (Stimulation Index) = DPN of a treated group divided by DPN of the appropriate control group.
DPN (Disintegrations Per Node) = DPM (Disintegrations Per Minute) divided by the number of lymph nodes.
In case of individual approach, SI values were calculated from the mean DPN values of the group
CLINICAL OBSERVATIONS:No mortality or signs of systemic toxicity were observed during the study. Test item precipitate was observed in the 50 and 25% (w/v) dose groups on Days 1-3. There were no Indications of any irritancy at the site of application.
BODY WEIGHTS:No treatment related effects were observed on body weights. No marked body weight loss (>5%) was detected for any experimental animals.
Any other information on results incl. tables
Disintegrations per minute (DPM)
Test item 50 % (w/v) in DMF: 3162.5 DPM
Test item 25 % (w/v) in DMF: 2880.5 DPM
Test item 10 % (w/v) in DMF: 4242.5 DPM
Negative (vehicle) control (DMF): 4441.5 DPM
Positive control (25% (w/v) HCA in DMF): 21332.5 DPM
Table No.4: Individual Body Weights for all Animals with Group Means
Identity Number |
Animal Number |
Test Group Name |
Initial Body Weight (g) |
Terminal Body Weight* (g) |
Change# (%) |
6961 |
1 |
Negative (vehicle) control DMF |
20.3 |
21.6 |
6.4 |
6974 |
2 |
20.9 |
21.7 |
3.8 |
|
6952 |
3 |
21.2 |
22.9 |
8.0 |
|
6963 |
4 |
21.8 |
22.6 |
3.7 |
|
|
|
MEAN |
21.1 |
22.2 |
5.5 |
6968 |
5 |
Test item in 50%(w/v) in DMF |
20.4 |
22.6 |
10.8 |
6953 |
6 |
20.7 |
21.1 |
1.9 |
|
6985 |
7 |
21.1 |
21.9 |
3.8 |
|
6958 |
8 |
21.7 |
22.8 |
5.1 |
|
|
|
MEAN |
21.0 |
22.1 |
5.4 |
6972 |
9 |
Test item in 25%(w/v) in DMF |
21.7 |
22.3 |
2.8 |
6982 |
10 |
20.5 |
20.8 |
1.5 |
|
6957 |
11 |
20.3 |
20.7 |
2.0 |
|
6967 |
12 |
21.8 |
22.7 |
4.1 |
|
|
|
MEAN |
21.1 |
21.6 |
2.6 |
6976 |
13 |
Test item in 10%(w/v) in DMF |
20.4 |
20.4 |
0.0 |
6989 |
14 |
20.9 |
22.3 |
6.7 |
|
6965 |
15 |
21.1 |
21.3 |
0.9 |
|
6977 |
16 |
21.9 |
22.3 |
1.8 |
|
|
|
MEAN |
21.1 |
21.6 |
2.4 |
6970 |
17 |
Positive control (25% (w/v) HCA in DMF) |
20.9 |
22.0 |
5.3 |
6979 |
18 |
20.7 |
21.3 |
2.9 |
|
6971 |
19 |
21.8 |
23.6 |
8.3 |
|
6981 |
20 |
21.3 |
21.2 |
-0.5 |
|
|
|
MEAN |
21.2 |
22.0 |
4.0 |
*: Terminal body weights were measured on Day 6.
#: = (Terminal Body Weight – Initial Body Weight) / Initial Body Weight x 100
Table No.5: DPM, DPN and Stimulation Index Values for all Groups
Proliferation assay:
Test Group Name |
Measured DPM / group |
DPM |
Number |
DPN |
Stimulation Index |
Background (5 % (w/v) TCA) |
74-31 |
- |
- |
- |
- |
(-) control (DMF) |
4494 |
4441.5 |
8 |
555.2 |
1.0 |
Test item 50 % (w/v) in DMF |
3215 |
3162.55 |
8 |
395.3 |
0.7 |
Test item 25 % (w/v) in DMF |
2933 |
2880.5 |
8 |
360.1 |
0.6 |
Test item 10 % (w/v) in DMF |
4295 |
4242.5 |
8 |
530 |
1.0 |
(+) control (25 % (w/v) HCA |
21385 |
21332.5 |
8 |
2666.6 |
4.8 |
The appearance of the lymph nodes was normal in the negative (vehicle) control group and in all test item treated groups. Larger than normal lymph nodes were observed in the positive control group.
The DPN values observed for the vehicle and positive control substance in this experiment were within the historical control range.
No mortality, cutaneous reactions or signs of toxicity were observed for the positive control substance in the study. A significant lymphoproliferative response (stimulation index value of 4.8) was noted for HCA in the main experiment. This value was considered to confirm the appropriate performance of the assay.
The DPN value of the negative control group was slightly above the general historical control range of vehicles, but this fact was considered not to adversely affect the results of the study. The DPN value of the positive control substance in this experiment was within the historical control range.
Table No.6: Summarized Clinical Observations
Group |
Animal No. |
CLINICAL OBSERVATIONS |
|||||
DAY 1 |
DAY 2 |
DAY 3 |
DAY 4 |
DAY 5 |
DAY 6 |
||
Negative control (DMF) |
1 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
2 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
|
3 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
|
4 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
|
4-amino-5- ethylsulfonyl-2- methoxybenzoic acid (50% (w/v) in DMF) |
5 |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
Symptom free |
Symptom free |
Symptom free |
6 |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
Symptom free |
Symptom free |
Symptom free |
|
7 |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
Symptom free |
Symptom free |
Symptom free |
|
8 |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
Symptom free |
Symptom free |
Symptom free |
|
4-amino-5- ethylsulfonyl-2- methoxybenzoic acid (25% (w/v) in DMF) |
9 |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
Symptom free |
Symptom free |
Symptom free |
10 |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
Symptom free |
Symptom free |
Symptom free |
|
11 |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
Symptom free |
Symptom free |
Symptom free |
|
12 |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
BT: symptom-free AT: symptom-free* |
Symptom free |
Symptom free |
Symptom free |
4-amino-5- ethylsulfonyl-2- methoxybenzoic acid (10% (w/v) in DMF) |
13 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
14 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
|
15 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
|
16 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
|
Positive control (25% (w/v) HCA in DMF) |
17 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
18 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
|
19 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
|
20 |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
BT: symptom-free AT: symptom-free |
Symptom free |
Symptom free |
Symptom free |
1. BT: before treatment, AT: after treatment
2. *: test item precipitate
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Remarks:
- STIMULATION INDEX IS < 3 (non sensitizer)
- Conclusions:
- The stimulation index values were 0.7, 0.6 and 1.0 at concentrations of 50, 25 and 10% (w/v), respectively. The substance does not have sensitisation potential (non-sensitizer) in the Local Lymph Node Assay.
- Executive summary:
The skin sensitisation test following dermal exposure was performed according to OECD Guideline 429 and EU method B.42. Based on the results of the Preliminary Compatibility Test, the test item was formulated in N,N-dimethylformamide (DMF) at a highest achievable concentration of 50 % (w/v). The Preliminary Irritation / Toxicity Test was performed in CBA/J Rj mice using two doses: 50 and 25 % (w/v) in DMF. The 50 % (w/v) was selected as top dose for the main test. Based on these results, four female CBA/J Rj mice per group received 50, 25 and 10 % (w/v) of tes item, DMF (vehicle, negative control) and 25 % (w/v) HCA (dissolved in DMF, positive control) in the main test.. The test item solutions were applied on the dorsal surface of ears of experimental animals (25 μL/ear) for three consecutive days (Days 1, 2 and 3). There was no treatment on Days 4, 5 and 6. On Day 6, the cell proliferation in the local lymph nodes was measured by incorporation of tritiated methyl thymidine (3HTdR) and the values obtained were used to calculate stimulation indices (SI). No mortality or signs of systemic toxicity were observed during the study. Test item precipitate was observed in the 50 and 25% (w/v) dose groups on Days 1-3. No treatment related body weight loss was observed in the test item treated animals. There were no indications of any irritancy at the site of application. The stimulation index values were 0.7, 0.6 and 1.0 at concentrations of 50, 25 and 10% (w/v), respectively. All validity criteria were fulfilled. In conclusion, the test item was shown to have no sensitisation potential (non-sensitizer) in the Local Lymph Node Assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.